tradingkey.logo

ImmunityBio Advances First Line BCG Naive NMIBC Program For Anktiva Plus BCG

ReutersJan 16, 2026 12:32 PM

- Immunitybio Inc IBRX.O:

  • IMMUNITYBIO ADVANCES FIRST-LINE BCG NAIVE NMIBC PROGRAM WITH ENROLLMENT EXCEEDING EXPECTATIONS AND POSITIVE INTERIM ANALYSIS FOR ANKTIVA® PLUS BCG

  • IMMUNITYBIO INC: EXPANDED ACCESS PROGRAM (EAP) OF RECOMBINANT BCG PROCEEDING WELL

  • IMMUNITYBIO : INTERIM ANALYSIS REQUESTED BY FDA DEMONSTRATED STATISTICALLY SIGNIFICANT LONGER DURATION OF COMPLETE RESPONSE WITH ANKTIVA + BCG

  • IMMUNITYBIO INC: ANTICIPATES SUBMITTING BLA TO U.S. FDA BY YEAR END 2026 FOR ANKTIVA PLUS BCG

  • IMMUNITYBIO INC - REQUESTS FDA CONSULTATION ON RECOMBINANT BCG USE

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI